Send Message
Andrew Goodwin holds a Ph.D. in the cellular and molecular basis of human disease, with research experience in infectious diseases and cancer. After 11 years as an academic scientist I now work on the regulatory side of drug development. Aside from my day job, I operate the websites BiotechDueDiligence and HSP90 Central that provide in-depth, reliable information and education for biotech investors and other readers. I have also contributed to Chimera Research Group, a publisher of subscription-based biopharmaceutical insight. In 2012 I was honored to be named one of the "Top 50 Industry Voices in Biotech" by FierceBiotech and Appeering. Visit my BiotechDueDiligence website for additional bio details.
  • Description: Independent / boutique research firm analyst. Trading frequency: Infrequent
  • Interests: ETFs, Retirement savings, Stocks - long
BiotechDueDiligence BiotechDueDiligence is a website dedicated to making you a better biotech investor. Biotechnology is a fascinating stock market sector that most individual investors are both intrigued by and deathly afraid of. The key to success is, like most things, doing your homework. You will find links and resources to ...More
BiotechDueDiligence BiotechDueDiligence ( is your source for In-depth research notes on select small- and mid-cap biotechnology/pharmaceutical companies. The site covers basic science, clinical trials, regulatory progress, partnering, business development, mergers and acquisitions, commericalization, ...More
Currently, there are no book details for bioduediligence.